PMID- 32489473
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231111
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 11
IP  - 15
DP  - 2020
TI  - Efficacy and Safety of Thalidomide for Chemotherapy-induced Nausea and Vomiting.
PG  - 4560-4570
LID - 10.7150/jca.45678 [doi]
AB  - Purpose: A substantial number of cancer patients discontinue chemotherapy due to 
      severe chemotherapy-induced nausea and vomiting (CINV). This study aimed to 
      evaluate the efficacy and safety of thalidomide (THD) in CINV. Methods: We 
      searched different databases to identify related studies that investigated the 
      efficacy and safety of THD in CINV. The primary outcomes were CINV in the acute 
      (0-24 h), delayed (24-120 h), and overall (0-120 h) phases, respectively. The 
      secondary outcomes were the safety of THD and the patients' quality of life 
      (QOL). Results: Fourteen randomized control trials (RCTs) including 1744 patients 
      (42% male) reported the risk ratio (RR) and 95%CI of the THD group versus control 
      group in reducing nausea and vomiting. Meta-analysis showed that THD 
      statistically enhanced the complete response rate of nausea and vomiting in the 
      delayed (nausea: RR = 1.69, 95%CI: 1.47-1.94; vomiting: RR = 1.38, 95%CI: 
      1.26-1.51) and overall phases (nausea: RR = 1.54, 95%CI: 1.31-1.81; vomiting: RR 
      = 1.31, 95%CI: 1.18-1.46). Furthermore, subgroup analysis based on THD dosage 
      (100 vs 200 mg/day) demonstrated no statistical significance with respect to 
      overlapping 95%CI. Thirty studies monitored the adverse events (AEs) of THD, all 
      under grade 3 based on the CTCAE criteria. We compared the eight most common AEs; 
      sedation, constipation, and drowsiness/dizziness were slightly frequent compared 
      with controls. Conclusion: THD is an effective adjuvant and a potential 
      alternative in reducing delayed and overall CINV. Other regimens might be added 
      for CINV during the acute phase.
CI  - (c) The author(s).
FAU - Wang, Nan
AU  - Wang N
AD  - Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, China.
AD  - Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Xu, Peng
AU  - Xu P
AD  - Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Liu, Yu
AU  - Liu Y
AD  - Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Zhao, Peng
AU  - Zhao P
AD  - Department of Medical Oncology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Ruan, Jian
AU  - Ruan J
AD  - Department of Medical Oncology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Zheng, Yi
AU  - Zheng Y
AD  - Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, China.
AD  - Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Jin, Junpei
AU  - Jin J
AD  - Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, China.
AD  - Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Wang, Shuqian
AU  - Wang S
AD  - Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Yao, Jia
AU  - Yao J
AD  - Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Xiang, Dong
AU  - Xiang D
AD  - Celilo Cancer Center, Oregon Health Science Center affiliated Mid-Columbia 
      medical center, The Dalles, OR, USA.
FAU - Zhang, Dai
AU  - Zhang D
AD  - Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Li, Na
AU  - Li N
AD  - Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, China.
AD  - Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Kang, Huafeng
AU  - Kang H
AD  - Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Dai, Zhijun
AU  - Dai Z
AD  - Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC7255358
OTO - NOTNLM
OT  - Chemotherapy-induced nausea and vomiting
OT  - Emesis
OT  - Thalidomide
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2020/06/04 06:00
MHDA- 2020/06/04 06:01
PMCR- 2020/01/01
CRDT- 2020/06/04 06:00
PHST- 2020/03/05 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/06/04 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - jcav11p4560 [pii]
AID - 10.7150/jca.45678 [doi]
PST - epublish
SO  - J Cancer. 2020 May 18;11(15):4560-4570. doi: 10.7150/jca.45678. eCollection 2020.